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ABSTRACT
Introduction: Breast cancer is the most common type of cancer that affects women. Human 
epidermal growth factor receptor 2 (HER2) is a gene that plays a significant role in the 
development of breast cancer. The aim of this study was to compare the survival of HER2-
positive breast cancer patients who received Herceptin with those who did not receive it in Yazd, 
Iran. Materials and Methods: Our study was an analytical cross-sectional study. Sampling was 
done on all patients with HER2-positive invasive ductal carcinoma (HER2 positive) who were 
referred to Shahid Sadoughi Hospital or Shahid Ramezanzadeh Hospital from 2003 to 2014. 
The data were collected using a questionnaire, which included questions on age, type of tumor, 
tumor grade, recurrence history, tumor size, number of lymph nodes, and whethr Hercepin was 
received or not received. Data were then entered into SPSS version 18 and analyzed by statistical 
tests. Results: The mean age of the patients was 50.78 ± 10.75 years. The mean survival time 
was 61.61 ± 2.93 months, and the mean recurrence time was 104.104 ± 41.3 months. The results 
also showed that there was no statistically significant difference between the 2 groups, despite 
the higher mean survival time and less recurrence time in patients receiving Herceptin compared 
with those who did not receive Herceptin (P>0.05). Conclusions: According to the results of 
this study, the efficacy of Herceptin as a neoadjuvant treatment in the survival of HER2-positive 
breast cancer patients has not been established.
INTRODUCTION
Breast cancer is one of the most common cancers in the 
world today. According to the US Joint Commission on Can-
cer, 1 in every 8 women is diagnosed with breast cancer (1). 
Nearly 12% of women in the United States suffer from 
breast cancer in their lifetime (2, 3). Breast cancer is the 
second leading cause of cancer death after lung cancer and 
is the most common cause of cancer death in women aged 
55 to 45 years. Treatment for breast cancer includes surgery, 
radiotherapy, chemotherapy, hormonal therapy, and biolog-
ical therapy. The treatment strategy is dependent on various 
factors; one of them is the human epidermal growth factor 
receptor 2 (HER2). HER2 is an oncogene that encodes trans-
membrane glycoprotein with tyrosine kinase activity called 
P-185, which belongs to the family of epithelial growth fac-
tor receptors (4). HER2 is normal at the lower level in epi-
thelial cells, but it increases in 15% to 30% of cases of breast 
cancer (5). This gene receives a protein called HER2 on the 
cell surface that receives growth signals (6). About 15% to 
30% of cancers are HER2-positive breast cancer, and the 
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neoadjuvant therapy performed to treat them includes Her-
ceptin (7). Herceptin is a specific monoclonal antibody that 
identifies and destroys tumor cells by targeting HER2 (8). 
Herceptin is a high-priced drug; for a treatment period of 
1 year, it costs about $70,000, which is about 40% of the 
cost of complete breast cancer treatment (9). Approximately 
65%  of HER2-positive breast cancer patients do not respond 
to Herceptin, and the disease progresses in approximately 
70% of those who have given an early response to Herceptin, 
1 year after the onset of treatment (10).
Considering the high prevalence of breast cancer and the 
use of Herceptin as a neoadjuvant treatment, the high cost, 
complications, and resistance to this drug, we determined 
that the survival of patients with HER2-positive breast can-
cer in patients receiving Herceptin compared with those who 
did not receive it in Yazd, Iran.
MATERIALS AND METHODS
Our study was a cross-sectional, retrospective study. The 
study population included 272 patients with HER2-positive 
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invasive ductal carcinoma (HER2 positive) who referred to 
Shahid Sadoughi Hospital or Shahid Ramezanzadeh Hos-
pital, Iran, between 2003 and 2014. A census survey meth-
od was conducted, and all patients with breast cancer were 
enrolled. However, patients with metastatic breast cancer 
and heart diseases, those receiving Herceptin, those whose 
records were incomplete, and those who could not afford 
telephone access were excluded. The records of the patients 
were collected from Shahid Sadoughi Hospital, Shahid Ra-
mezanzadeh Hospital, and Dr Mortazavi Zadeh’s office. 
Information including patient’s age, type of tumor, tumor 
grade, relapse date, tumor size, and the number of lymph 
nodes was recorded. Patients’ telephone numbers were also 
recorded. Information about receiving Herceptin as well as 
their survival was collected through phone calls. The ques-
tionnaire was recorded. Survival meant the mortality rate of 
patients until 2014. In the next stage, patients were staged. 
In this study, patients who received at least 4 courses of 
Herceptin were assigned to receive Herceptin. The reason 
is that considering the cost in the years of the study, which 
was based on the results of various studies that showed that, 
on the basis of the prescription of a male patient, 9-week 
treatment with Herceptin may be sufficient, the Ministry of 
Health decided to limit the treatment to 9 weeks; therefore, 
some patients received Herceptin for 1 year while some of 
them received it for less than 1 year. There was also a need 
for financial intelligence analysis, because despite planning, 
1 year later, Herceptin was discontinued in the middle of the 
test. Finally, the test results were analyzed using SPSS ver-
sion 18, chi-square, and Fisher tests. Patient survival time 
was calculated by reducing the date of diagnosis from the 
date of the patient’s death or the disease recurrence date.
RESULTS
The results of our study showed that the mean age of the par-
ticipants in the study was 50.78 ± 10.75 years. The minimum 
age and the maximum age of the participants were 25 and 
85 years, respectively. The age group, Herceptin, grade, stage, 
ER, PR, P53, Ki-67, death events, and recurrence events, and 
their abundance of the study group are presented in Table-1.
The analysis of the results of our study by the chi-square 
and Fisher tests showed that there was a significant relation-
ship of the death event with the stage of the tumor and that 
of the incidence of recurrence with the stage and grade of the 
tumor (P<0.05).
The survival of patients was analyzed by the Kaplan-Mei-
er test. The results showed that the average survival time us-
ing the Kaplan-Meier test was 119.61 ± 2.93 minutes, the 
curve of which is shown in Figure-1.
The mean survival time of patients according to the vari-
ables of the study was investigated using the log-rank test, 
the results of which are presented in Table 2. The results of 
this study showed that the mean survival time in patients 
receiving Herceptin was 19.11, and in those who did not re-
ceive Herceptin, it was 10.99. Despite the higher mean sur-
vival time of patients receiving Herceptin, compared with 
those not receiving it, there was no statistically significant 
difference between the 2 groups (P>0.05).
The results of our study on the mean survival time of pa-
tients in terms of the grade of the disease and receiving Her-
ceptin showed that the average survival rate of grade I patients 
receiving Herceptin and those not receiving it, was not measur-
able, because all patients in both the groups survived until the 
end of the study. The mean survival times of grade II patients 
receiving Herceptin and those who did not receive were 11.07 
and 102.58 months, respectively, with a statistically significant 
difference (P=0.061). There was no statistically significant dif-
ference between the mean survival time of grade III patients 
receiving Herceptin and those who were not (P=0.962).
Also, the results of the study on the mean survival time 
in terms of the stage of the disease and receiving Herceptin 
showed that none of the 11 patients who received Herceptin 
and was in stage I died, so the average survival rate for this 
group could not be obtained. The mean survival times of stage 
II patients who received Herceptin, and those who did not, 
were 11.16 and 131.63 months, respectively (P=0.220). The 
mean survival times of stage III patients who received Her-
ceptin and those who did not were 10.088 and 87.95 months, 
respectively. There was no statistically significant difference 
between them (P=0.456).
Table 1. Frequency of patients according to the variables 
studied
PercentFrequencySubgroupVariable
2/26<30Age group
12/13330-39
29/48040-49
38/610550-59
12/13360-69
5/515>70
41/9114YesReceiving herceptin
45/2123No
6/317IGrade
43/4118II
28/778III
8/122IStage
46/0125II
33/190III
42/6116NegativeER
53/7146Positive
51/5140NegativePR
44/5121Positive
26/873NegativeP53
31/686Positive
23/564NegativeKi-67
25/770Positive
18/450Yes`Death
71/3194No
19/553YesRecurrence
63/6173No
ER: Esterogen receptor, ; PR: Progestron receptor
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The recurrence of cancer in patients was analyzed by 
the Kaplan-Meier test. The results showed that the mean re-
currence time using the Kaplan-Meier test was 104/104 ± 
41.3 months, the curve of which has been shown in Figure 2.
The mean recurrence time of patients according to the 
variables of the study was investigated using the log-rank 
test, the results of which are presented in Table 3. The results 
of this study showed that the mean recurrence time of pa-
tients receiving Herceptin was 10.47% and of those who did 
not receive was 21.25%. However, the mean recurrence time 
of patients receiving Herceptin was significantly lower than 
that of those who received Herceptin. There was no statisti-
cally significant difference between these 2 groups (P>.05).
The results of our study on the mean recurrence time of 
patients in terms of the grade of the disease and receiving 
Herceptin showed that the mean recurrence time of grade I 
patients who received Herceptin and or who did not was not 
measurable because all patients from these 2 groups were alive 
Table 2. Frequency and descriptive index of survival time in terms of the variables studied
P valueSurvival meanAlive numberDeathTotal numberSubgroupVariable
0.054117.1999 (90.0%)11110YesReceiving herceptin
190.7987 (75.7%)28115No
0.122---4 (100%)04<30Age group
108.0526 (89.7%)32939-30
115.6656 (87.5%)86449-40
112.9775 (82.4%)169159-50
95.7118 (66.7%)92769-60
99.857 (70%)310>70
0.145---12 (100%)012IGrade
108.6082 (87.2%)1294II
98.5455 (79.7%)1469III
<0.001115.9217 (94.4%)118IStage
122.4396 (91.4%)9105II
97.8253 (71.6%)2174III
0/322108.3582 (80.4%)20102NegativeER
117.7699 (84.6%)18117Positive
0/313111.4298 (81.0%)23121NegativePR
114.1283 (85.6%)1497Positive
0/665114.9947 (81.0%)1158NegativeP53
116.1372 (86.7%)1183Positive
0/065118.0752 (92.9%)456NegativeKi-67
92.2652 (83.9%)1062Positive
Abbreviations: ER: Esterogen receptor, ; PR: Progestron receptor
Figure 1. Survival Curve of Patients Studied by the Month Figure 2.  Recurrence Curve in Patients Evaluated by the Month
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at the end of the study. The mean relapse times of grade II 
patients who received Herceptin and those who did not were 
92.34 and 10.58 months, respectively, with a significant dif-
ference (P=0.491). In other words, cancer recurred sooner in 
patients who received Herceptin than those who did not. There 
was no significant difference between the mean relapse time 
of grade III patients receiving Herceptin and not (P=0.409).
Also, the results of the study on the mean survival time in 
terms of stage I patients receiving Herceptin showed that those 
who received Herceptin had no recurrent events (11); therefore, 
the mean recurrence time could not be obtained for this group. 
However, the mean recurrence time for the group of stage I 
patients who did not receive Herceptin was 50.92 months. The 
median recurrence times of stage II patients who received Her-
ceptin and those who did not were 103.39 and 17/112 months, 
respectively, meaning that breast cancer soon recurred in stage 
II patients who received Herceptin. There was, however, sta-
tistically no significant difference between them (P=0.515). 
The median recurrence times of stage III patients who received 
Herceptin and those did not were 88.81 and 82.49 months, re-
spectively, showing that there was no statistically significant 
difference between them (P=0.896).
DISCUSSION
The aim of this study was to evaluate the survival of 
HER2-positive breast cancer patients who received Her-
ceptin compared with those who did not receive it.
The mean age of 272 patients studied at the time of di-
agnosis was 50.78 ± 10.75 years, and most patients were 
in the age group of 50 to 59 years. In a study conducted in 
Tehran (11), the mean age of patients was 51.3 years, which 
is consistent with our study results. Other studies have also 
reported that an average age of breast cancer patients is be-
tween 45 and 50 years (12), which is consistent with our 
study. The age distribution of women with breast cancer in 
the country indicates that the diagnostic age of the disease in 
the country is lower than that in Western Europe and North 
America, and also that women in Iran are more likely to de-
velop breast cancer (13).
Of the 272 patients studied in our research, 50 (18.4%) 
died. In a study conducted in 2011 (11), the death rate of 
patients suffering from breast cancer was 18.8%, which is 
similar to the results of our study. In our study, the mean 
survival time was 2.93; however, there was no statistically 
significant relationship between the age and survival time. 
The relationship between the age and survival time of pa-
tients in different studies had different results. The results 
of a study conducted in 2008 (14) and that of another study 
conducted in 2009 (15) showed an inverse relationship be-
tween the patient’s age and the survival time of the patients; 
however, no significant correlation was found between the 
age and the survival time of the patients, which is consis-
tent with the results of our study (16, 17). It seems that the 
most important factor affecting the difference between the 
Table 3. Frequency and descriptive indices of recurrence time according to the variables studied
P valueSurvival meanNo recurrent 
number
Recurrent numberTotal numberSubgroupVariable
0.569104.3790 (81.1%)21111YesReceiving herceptin
105.2179 (73.8%)28107No
0.217---2 (100%)0230 >Age group
86.3121 (67.7%)103130-39
102.5451 (82.3%)116240-49
111.5769 (80.2%)178650-59
106.0020 (76.9%)62660-69
90.946 (54.5%)51170 <
0.005*108.8316 (88.9%)218IStage
115.0190 (85.7%)15105II
90.1144 (65.7%)2367III
0.004*---12 (100%)012IGrade
105.7276 (85.4%)1389II
84.2845 (67.2%)2267III
0.847106.5775 (77.3%)2297NegativeER
108.9391 (78.4%)25116Positive
0.249103.7288 (75.2%)29117NegativePR
108.6178 (81.3%)1896Positive
0.862106.4747 (73.4%)1764NegativeP53
105.5461 (78.2%)1778Positive
0.40997.8945 (78.9%)1257NegativeKi-67
82.6646 (74.2%)1662Positive
ER: Esterogen receptor, ; PR: Progestron receptor
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age and survival time of patients is the number of patients 
in the study. Therefore, if the sample size is bigger, a mean-
ingful relationship between the age and survival time can 
be established. In our study, the average survival time of 
patients receiving Herceptin was 19/117 months and that 
of those who did not receive Herceptin was 10.98 months. 
This difference was not statistically significant. Many stud-
ies have been conducted on the effect of Herceptin on the 
survival time of patients with breast cancer, yielding con-
troversial results. In some of these studies, Herceptin was 
shown to increase the survival time of patients, whereas in 
other studies, it had no effect on the patients suffering from 
the breast cancer. In a study conducted by Smith, the survival 
rate of patients treated with Herceptin was higher than for 
those who did not receive Herceptin treatment, and this rela-
tionship was statistically significant, which is consistent with 
our study outcomes (18). The reason for this difference can 
be attributed to the difference in the type of study—the study 
by Smith was performed as a randomized controlled trial, 
but ours was a cross-sectional and retrospective study. In one 
of the studies conducted in 2013, a group of patients was 
treated with doxorubicin, cyclophosphamide, and paclitaxel, 
whereas another group was treated with the combination of 
the above drugs and Herceptin. The study results showed an 
additional 10-year survival time in the latter group; in addi-
tion, the relationship between the age and the survival time 
was significant (19). In another study, the survival rate of 
1 year in patients receiving Herceptin was 26%, whereas it 
was 12% in the group not receiving Herceptin (20). In anoth-
er study, conducted in France, the patients were divided into 
2 groups. The first group received 12-month treatment with 
Herceptin and the second group received 6-month treatment 
with it. The results of this study showed that the survival 
time in the first group was 2 years more than that in the sec-
ond group (21). Our study showed a statistically significant 
difference between the mean survival rate of patients who 
had positive or negative ER and Herceptin receptors. In 
several studies, the effects of estrogen receptors on surviv-
al rates were significant (11, 21, 22), which did not match 
the results of our study. The results of a study conducted in 
1999 (23) and another conducted in 2001 (24) showed that 
positive or negative estrogen receptors do not play a role in 
the survival of patients (23, 24), which was consistent with 
our study results. The average survival time of patients in 
terms of positive or negative PR in our study, contrary to 
some other studies, was not significant (25, 26), which was 
not consistent with our study outcomes. However, in a 2008 
study, a significant relationship was found between the mean 
survival time and positive or negative PR (27, 28), which 
was consistent with the results of our study. The stage of 
the disease is thought to be an effective factor in the sur-
vival of patients. In our study, in the groups of patients who 
did not receive Herceptin and were at the first, second, and 
third stages, the survival times were 110/1, 118/89, and 
87/95 months, respectively. The difference was statistically 
significant. In a study of 2011 (11), patients diagnosed with 
the first stage of the disease showed a higher survival than 
those who were at the second and third stages, and they had 
a significant relationship (11).
CONCLUSION
In our study, the difference in mean survival time in the 
group receiving Herceptin was statistically significant at 
the second stage. In the main study that led to the confirma-
tion of Herceptin by the Food and Drug Administration, all 
tests for HER2 positive status were rechecked in a reference 
laboratory, something which is virtually impossible in our 
country because there is no reference laboratory in Iran for 
rechecking.
Our study failed to demonstrate the efficacy of Herceptin 
adjuvant therapy in patients suffering from breast cancer. 
According to this study, as well as the results of other stud-
ies, a general screening for the use of Herceptin in Iran as an 
adjuvant treatment therefore seems necessary.
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